Health TrialsbyHealthPanel

Magnesium Sulfate as an Adjuvant to Lidocaine in MPDS Trigger Point Injections Assessed by VAS and sEMG.

ConditionMyofascial Pain Dysfunction Syndrome
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-70
SponsorCairo University

About this trial

Two groups of patients diagnosed with Myofascial Pain Dysfunction Syndrome (MPDS) will be included in this study. One group will receive trigger point injections of lidocaine alone. The other group will receive trigger point injections of lidocaine combined with magnesium sulfate. The study aims to compare the effectiveness of both treatments in reducing pain and improving muscle function. Patients will be assessed using a pain scale (VAS) and surface electromyography (sEMG) to measure muscle activity.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Age between 18 and 70 years.

Clinical diagnosis of Myofascial Pain Dysfunction Syndrome (MPDS).

Presence of active myofascial trigger points in accessible muscles (e.g., masseter, temporalis, upper trapezius).

Pain duration ≥ 3 months.

Disqualifiers

Known allergy or hypersensitivity to Lidocaine, Magnesium Sulfate, or related agents.

Current use of anticoagulants or history of bleeding disorders.

Systemic or local infection at or near the injection site.

History of fibromyalgia, central pain syndromes, or cancer-related pain.

Trial design

Design model

Parallel

Treatments tested in this trial

  • Lidocaine 2% (preservative-free, without vasoconstrictor)

    Drug

    Using 25-27G sterile disposable needle, intramuscular injection of 2%preservative-free solution of lidocaine without vasocostrictor, 1.8 ml at the most painful trigger points with "Fast-in, fast out" or "peppering" method and inject the solution slowly.

  • Lidocaine 2% + Magnesium Sulfate 10% (combination)

    Drug

    Using 25-27G sterile disposable needle, intramuscular injection of 2%preservative-free solution of lidocaine without vasocostrictor mixed with 10%magnesium sulphate , Approx. 3.8 ml per point (1.8 ml Lidocaine + 2 ml MgSO₄) at the most painful trigger points with "Fast-in, fast out" or "peppering" method and inject the solution slowly.

Treatment groups

28 Participants
are divided into 2 treatment groups
Group A: Lidocaine injectionActive comparator 1 intervention
Group B: Injection of Magnesium sulfate with LidocaineExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Pain reduction.

Pain intensity will be assessed using the Visual Analogue Scale (VAS) ranging from 0 to 10 cm, where 0 indicates no pain and 10 indicates worst imaginable pain.

Time frame
Baseline, 1week, 2 weeks post-injection.
2

Muscle activity improvement.

Muscle activity will be assessed using surface electromyography (sEMG) by measuring Maximum Voluntary Contraction (MVC) in microvolts (µV). Higher values indicate improved muscle activity.

Time frame
Baseline, 1 week, 2 weeks post-injection

Secondary outcomes

1

Pain experienced during injection

Pain during injection will be assessed immediately after injection using the Visual Analogue Scale (VAS) ranging from 0 to 10 cm, where 0 indicates no pain and 10 indicates worst imaginable pain.

Time frame
Immediately after injection

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Cairo University

Lead sponsor

Source ClinicalTrials.gov
Apply now